Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5- fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model

Journal of Urology

Volumn 162, Issue 3 I, 1999, Pages 949-954

  Shirakawa, Toshiro ^b   Gardner, Thomas A ^a   Ko, Song Chu ^b   Bander, Neil ^b   Woo, Savio ^b   Gotoh, Akinobu ^b   Kamidono, Sadao ^b   Chung, Leland W K ^b   Kao, Chinghai ^b  

^a INDIANA UNIVERSITY   (United States)

^b NONE

Author keywords

Animal model; Experimental therapeutics; Human kidney cancer

Indexed keywords

ACICLOVIR; CONNEXIN 43; CYTOSINE DEAMINASE; FLUOROURACIL; THYMIDINE KINASE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; ELECTRON MICROSCOPY; GAP JUNCTION; GENE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROUS SARCOMA ONCOVIRUS;

EID: 0032851547     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199909010-00096     Document Type: Article

References (39)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer Statistics, 1998. CA Cancer J. Clin., 48: 6, 1998.
2. Motzer, R. J., Bander, N. H. and Nanus, D. M.: Renal-cell carcinoma [see comments]. N. Engl. J. Med., 335: 865, 1996.
3. Silverberg, E. and Lubera, J.: Cancer statistics, 1987. CA Cancer J. Clin., 37: 2, 1987.
4. Myers, M. H. and Gloeckler, L. A.: Cancer patient survival rate: SEER program results for 10 years of follow-up. CA, 39: 21, 1989.
5. Muss, H. B.: Renal cell carcinoma. Philadelphia: J. B. Lippincott Co., 1991.
6. Belldegrum, A., Tso, C. L. and Kaboo, R.: Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2 based therapy. J. Immunother., 19: 149, 1996.
7. Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., Hauda, K. M., Beck, L. A., Leiferman, K. M., Owens, A. H., Jr., Piantadosi, S., Dranoff, G., Mulligan, R. C., Pardoll, D. M. and Marshall, F. F.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57: 1537, 1997.
8. Robertson, C. N., Linehan, W. M., Pass, H. I., Gomella, L. G., Hass, G. P., Berman, A., Merino, M. and Rosenberg, S. A.: Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine-activated killer cells. J. Urol., 144: 614, 1990.
9. Dutcer, J., Fisher, R., Weis, G., Aronson, F., Margolin, K., Louie, A. and Atkins, M.: Outpatient subcutaneous (sc) interleukin-2 (IL-2) plus α-interferon (IFN) in metastatic renal cell cancer (RCC): 3-year follow-up of the Cytokine Working Group study. Am. Soc. Clin. Oncol., 14: 332, 1995.
10. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C. A., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S. and White, D. E.: Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7: 1863, 1989.
11. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., Seipp, C. A. and White, D. E.: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210: 474, 1989.
12. Cheon, J., Ko, S. C., Gardner, T. A., Shirakawa, T., Gotoh, A., Kao, C. and Chung, L. W. K.: Chemogene therapy for osteosarcoma: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther., 4: 359, 1997.
13. Lan, K. H., Kanai, F., Shiratori, Y., Ohashi, M., Tanaka, T., Okudaira, T., Yoshida, Y., Hamada, H. and Omata, M.: In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res., 57: 4279, 1997.
14. Kanai, F., Lan, K. H., Shiratori, Y., Tanaka, T., Ohashi, M., Okudaira, T., Yoshida, Y., Wakimoto, H., Hamada, H., Nakabayashi, H., Tamaoki, T. and Omata, M.: In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res., 57: 461, 1997.
15. Mullen, C. A., Kilstrup, M. and Blaese, R. M.: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33, 1992.
16. Dilber, M. S., Abedi, M. R., Christensson, B., Bjorkstrand, B., Kidder, G. M., Naus, C. C., Gahrton, G. and Smith, C. I.: Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res., 57: 1523, 1997.
17. Elshami, A. A., Saabedra, A., Zhang, H., Kucharczuk, J. C., Spray, D. C., Fishman, G. I., Amin, K. M., Kaiser, L. R. and Albelda, S. M.: Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther., 3: 85, 1996.
18. Fick, J., Barker, F. G. I., Dazin, P., Westphale, E. M., Beyer, E. C. and Israel, M. A.: The extent of hepatcellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA, 92: 11071, 1995.
19. Hoganson, D. K., Batra, R. K., Olsen, J. C. and Boucher, R. C.: Comparision of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res., 56: 1315, 1996.
20. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K. and Yamasaki, H.: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93: 1831, 1996.
21. Domin, B. A., Mahony, W. B. and Zimmerman, T. P.: Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem. Pharmacol., 46: 503, 1993.
22. Ebert, T., Bander, N. H., Finstand, C. L., Ramsawak, R. D. and Old, L. J.: Establishment and characterization of human renal cell cancer and normal kidney cell lines. Cancer Res., 50: 5531, 1990.
23. McKiernan, J. M., Buttyan, R., Bander, N. H., Stifelman, M. D., Katz, A. E., Chen, M. W., Olsson, C. A. and Sawczuk, I. S.: Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res., 57: 2362, 1997.
24. Shinoura, N., Chen, L., Wani, M. A., Kim, Y. G., Larson, J. J., Warnick, R. E., Simon, M., Menon, A. G., Bi, W. L. and Stambrook, P. J.: Protein and messenger RNA expression of connexin 43 in astrocytomas: implications in brain tumor gene therapy. J Neurosurg., 84: 839, 1996.
25. Graham, F. L. and Prevec, L.: Methods for construction of adenovirus vectors. Mol. Biotech., 3: 207, 1995.
26. Gleave, M., Hsieh, J. T., Gao, C. A., von Eschenbach, A. C. and Chung, L. W. K.: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 51: 3753, 1991.
27. Musil, L. S. and Goodenough, D. A.: Biochemical analysis of connexin43 intercellular transport, phosphorylation, and assembly into gap junctional plaques. J. Cell Biol., 115: 1357, 1991.
28. Trinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C. and Huber, B. E.: Enzyme/prodrug gene therapy: comparision of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ ganciclovir enzyme/prodrug system in a human colorectal carcinoma cell line. Cancer Res., 55: 4808, 1995.
29. Hillis, G. S., Duthie, L. A., Mlynski, R., McKay, N. G., Mistry, S., MacLeod, A. M., Sim, P. and Haites, N. E.: The expression of connexin 43 in human kidney and cultured renal cells. Nephron, 75: 458, 1996.
30. Noguchi, M., Nomata, K., Watanabe, J., Kanetake, H. and Saito, Y.: Changes in the gap junctional intercellular communication in renal tubular epithelial cells in vitro treated with renal carcinogens. Cancer Lett., 122: 77, 1998.
31. Krutovskikh, V. A., Mesnil, M., Mazzoleni, G. and Yamasaki, H.: Inhibition of rat liver gap junction intercellular communication by tumor-promoting agents in vivo. Lab. Invest., 72: 571, 1995.
32. Ruch, R. J.: The role of gap junctional intercellular communication in neoplasia. Am. Clin. Lab. Sci., 24: 216, 1994.
33. Gardner, T. A., Ko, S. C., Kao, C., Shirakawa, T., Cheon, J., Gotoh, A., Wu, T. T., Sikes, R. A., Zhau, H. E., Cui, Q., Balian, G. and Chung, L. W. K.: Exploiting stromal-epithelial interaction for model development and new strategies of gene therapy for prostate cancer and osteosarcoma metastases. Gene Ther. Mol. Biol., 2: 41, 1998.
34. Ko, S. C., Cheon, J., Kao, C., Gotoh, A., Shirakawa, T., Sikes, R. A., Karsenty, G. and Chung, L. W. K.: Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res., 56: 4614, 1996.
35. Bonnekoh, B., Greenhalgh, D. A., Bundman, D. S., Eckhardt, J. N., Longley, M. A., Chen, S. H., Woo, S. L. C. and Roop, D. R.: Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J. Invest. Dermatol., 104: 313, 1995.
36. Donahue, H. J., Mcleod, K. J., Rubin, C. T., Andersen, J., Grine, E. A., Hertzberg, E. L. and Brink, P. R.: Cell-to-cell communication in osteoblastic networks: cell line-dependent hormonal regulation of gap junction function. J. Bone Mineral Res., 10: 881, 1995.
37. Treat, J., Kaiser, L. R., Sterman, D. H., Litzky, L., Davis, A., Wilson, J. M. and Albelda, S. M.: Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase I trial (BB-IND 6274). Human Gene Ther., 7: 2047, 1996.
38. Eck, S. L., Alavi, J. B., Alavi, A., Davis, A., Hackney, D., Judy, K., Mollman, J., Phillips, P. C., Wheeldon, E. B. and Wilson, J. M.: Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Human Gene Ther., 7: 1465, 1996.
39. Pelin, K., Hirvonen, A. and Linnainmaa, K.: Expression of cell adhesion molecules and connexins in gap junctional intercellular communication deficient human mesothelioma tumour cell lines and communication competent primary mesothelial cells. Carcinogenesis, 15: 2673, 1994.